Table 7.

Overview of clinical therapeutics for clinical trials in ARDS/ALI.

Target	Interventions	Indications	Primary endpoint	Participants	Status	References
C1/MBL	RLS-0071	COVID-19-induced severe ARDS	Frequency and severity of Adverse Events, including Serious Adverse Events, by treatment group and dose level, including the frequency of premature discontinuation of study intervention due to Adverse Events	42	Not yet recruiting	NCT04574869 (P1)
C3	AMY-101	COVID-19-induced severe ARDS	1) The proportion of patients who are alive, without evidence of ARDS; and 2) The proportion of patients assigned to each category, of a six-category ordinal scale.	144	Not yet recruiting	NCT04395456 (P1-P2)
C3	APL-9	COVID-19-induced severe ARDS	Cumulative incidence of treatment emergent serious adverse events and treatment-emergent adverse events	66	Recruiting	NCT04402060 (P2)
C5	Ravulizumab	COVID-19-induced severe ARDS/ALI/pneumonia	Survival (based on all-cause mortality) at Day 29	270	Active, not recruiting	NCT04369469 (P3)
C5	Zilucoplan®	COVID-19-induced severe ARDS	1) Mean change in oxygenation [Time Frame: at predose, day 6 and day 15 (or at discharge, whichever comes first)] defined by Pa02/FiO2 ratio while breathing room air, P(Aa)O2 gradient and a/A pO2 ratio; and 2) Median change in oxygenation [Time Frame: at predose, day 6 and day 15 (or at discharge, whichever comes first)] defined by PaO2/FiO2 ratio while breathing room air, P(Aa)O2 gradient and a/A pO2 ratio	81	Completed	NCT04382755 (P2)
C5	SOLIRIS®	COVID-19-induced severe ARDS/ALI/pneumonia		N/A	No longer available	NCT04355494 (P2)
C5	SOLIRIS®	COVID-19	Mortality	N/A	Available	NCT04288713

ALI, acute lung injury; ARDS, acute respiratory distress syndrome; MBL, mannan-biding lectin; N/A, not available.